Lilly’s demand for diabetes and weight loss drugs is increasing worldwide. The launch of this drug in India is a big opportunity. India is the most populous country in the world and cases of obesity and diabetes are increasing here. The company claims that this drug can prove to be a new and effective way of improving metabolic health and weight loss.
Diabetes and obesity in India are serious problems
Lilly India said that obesity and type 2 diabetes are becoming a major health problem in India. Around 10.1 million people in India suffer from diabetes and obesity is a major cause of diabetes. This means that this is a serious concern that needs attention.
There is a lot of medicine being used in America and Europe
Maunzaro’s chemical name is Tirzepatide, currently being sold in the UK and Europe for both diabetes and weight loss. In America, it is found for obesity in the name of Zepbound. Experts believe that the market of obesity reducing drugs is going to be very large in the coming years. They estimate that by 2030 the sale of these drugs can reach $ 150 billion.
How does this medicine work?
This medicine is taken once a week, which can cost from ₹ 14,000 to ₹ 17,500 per month as per the dose given by the doctor. It is the first drug for obesity and type-2 diabetes that activates GIP and GLP-1 hormone receptors. This medicine can give a new and effective treatment, which can improve the metabolic health of patients. It helps in increasing the production of insulin in the body, reducing glucagon levels, improving insulin sensitivity and controlling hunger. It reduces the amount of fat in the body and regulates lipid utilization.
How much weight can be reduced by silence?
New England Journal of Medicine (RefereeAccording to the clinical trial published in the published in the clinical trial, people who were taking Maunzaro with diet and exercise, lost average 21.8 kg (at 15 mg dose) and 15.4 kg (at 5 mg dose) in 72 weeks.
GLP-1 increasing demand for drugs
The demand for GLP-1 class medicines is increasing rapidly for the treatment of diabetes and obesity. This market is now worth hundreds of billion dollars. The patent of Semaglutide, a major drug of this category, is ending in March 2025. After this, many Indian companies are preparing to launch a generation version of this medicine.
Disclaimer: This article is only for general information. This can not be an option for any medicine or treatment in any way. Always contact your doctor for more information. NBT does not take responsibility for its truth, accuracy and impact.
